# Eyal Agmoni

> Eyal Agmoni is a Series A investor at Japan-Israel Hi-Tech Ventures backing Medical Device. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Japan-Israel Hi-Tech Ventures](https://shizune.co/investors/profile/japan-israel-hi-tech-ventures)
- Total investments: 10
- Last investment: Jul 2025
- Lead investor: 90%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eyal-agmoni-7930572

Eyal Agmoni is a Series A investor at Japan-Israel Hi-Tech Ventures focused on Medical Device and Pharmaceutical. Eyal Agmoni is the Founder of Japan-Israel Hi-Tech Ventures. Eyal Agmoni attended NYU Stern School of Business.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 3 | 30% |
| Pharmaceutical | 2 | 20% |
| Artificial Intelligence | 2 | 20% |
| Apps | 1 | 10% |
| Drones | 1 | 10% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 20% |
| Seed | 1 | 10% |
| Series B | 1 | 10% |
| Funding Round | 1 | 10% |
| Private Equity | 1 | 10% |

6 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| XTEND | XTEND develops AI-assisted tactical Unmanned Aircraft Systems (UAS) and the XOS operating system for remote operations. Its platforms are designed for military, security, and industrial applications, enabling intuitive control and rapid deployment. XTEND's technology supports multi-platform control, exchangeable payloads, and integration withthird-party software for diverse mission needs. | $30M | Series B | Jul 15, 2025 |  |
| XTEND | XTEND develops AI-assisted tactical Unmanned Aircraft Systems (UAS) and the XOS operating system for remote operations. Its platforms are designed for military, security, and industrial applications, enabling intuitive control and rapid deployment. XTEND's technology supports multi-platform control, exchangeable payloads, and integration withthird-party software for diverse mission needs. | $40M | Series B | May 08, 2024 |  |
| Trobix Bio | Trobix Bio is a company that develops and commercializes antibacterial products. It has developed platform technologies called ActiSense and GOTrap for developing high-quality products that remove the threat of antimicrobial resistance. | $3M | Series A | Mar 30, 2023 |  |
| Zsquare | Zsquare has developed the only scalable endoscopic platform capable of transmitting high resolution images in flexible, single-use endoscopes, through polymeric fibers of any shape or size. Zsquare’s imaging technology outperforms existing technologies by delivering higher quality visualizations through smaller diameters than those found inreusable endoscopy systems.Zsquare’s polymeric fiber enables the housing of inexpensive optics with no electronics in a single-use shell, and expensive components in a detachable, reusable imaging core. This platform feature allows the use of a single core with various interchangeable shells which offer differing capabilities for different indications, facilitating any type of endoscopy procedure at a lower costs per-use. | $15M | Private Equity | Mar 01, 2022 |  |
| X-trodes | X-trodes is a technology start-up that develops unique wearable, wireless technology, and advanced analytics of biopotential signals. | $4.5M | Seed | Oct 18, 2021 |  |
| Pepticom Ltd. | Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $2.6M | Venture - Series Unknown | Mar 09, 2021 |  |
| Trobix Bio | Trobix Bio is a company that develops and commercializes antibacterial products. It has developed platform technologies called ActiSense and GOTrap for developing high-quality products that remove the threat of antimicrobial resistance. | $3M | Series A | Jul 29, 2020 |  |
| Zsquare | Zsquare has developed the only scalable endoscopic platform capable of transmitting high resolution images in flexible, single-use endoscopes, through polymeric fibers of any shape or size. Zsquare’s imaging technology outperforms existing technologies by delivering higher quality visualizations through smaller diameters than those found inreusable endoscopy systems.Zsquare’s polymeric fiber enables the housing of inexpensive optics with no electronics in a single-use shell, and expensive components in a detachable, reusable imaging core. This platform feature allows the use of a single core with various interchangeable shells which offer differing capabilities for different indications, facilitating any type of endoscopy procedure at a lower costs per-use. | $10M |  |  |  |
| Pepticom Ltd. | Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $5M | Series A |  |  |
| Pepticom Ltd. | Pepticom is a privately held AI company with headquarters in Israel committed to offering AI peptide drug discovery solutions for a better and healthier world. It is the leader in the emerging peptide drugs software solutions, AI and prediction tools that allow research centers, pharma and agriculture companies to accelerate innovative moleculesdiscovery while reducing time, costs and risks. Pepticom operates in various markets; past successful discoveries include peptide molecules related to metabolic diseases and Immuno-modulators. | $6.6M | Series A |  |  |

10 of 10 investments shown.

## Co-investors
- [ClalTech](https://shizune.co/investors/profile/claltech) — VC Fund, 2 deals together
- [Protego Ventures](https://shizune.co/investors/profile/protego-ventures) — VC Fund, 2 deals together
- [Union Tech Ventures](https://shizune.co/investors/profile/union-tech-ventures) — VC Fund, 2 deals together
- [Welltech Ventures](https://shizune.co/investors/profile/welltech-ventures) — VC Fund, 2 deals together
- [Aliya Capital Partners](https://shizune.co/investors/profile/aliya-capital-partners) — VC Fund, 1 deal together
- [TAU Ventures](https://shizune.co/investors/profile/tau-ventures) — VC Fund, 1 deal together

## About Japan-Israel Hi-Tech Ventures

VC Fund

Japan-Israel Hi-Tech Ventures is a venture fund operated by Singapore-based asset management firm Chartered Group.

1 contacts available at Japan-Israel Hi-Tech Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Eyal Agmoni | Founder | https://shizune.co/investors/profile/eyal-agmoni |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Eyal Agmoni invest in?

Eyal Agmoni invests primarily in Medical Device, Pharmaceutical and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eyal Agmoni last invest?

The most recent investment recorded for Eyal Agmoni closed in Jul 2025. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co